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background: The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) is designed to identify 
factors influencing the selection of antithrombotic treatment to prevent stroke in patients with non-valvular atrial fibrillation (AF). While Phase I 
assessed the prescription pattern before the approval of the new oral anticoagulants, Phase II of the registry was instituted early after availability of 
dabigatran to assess the comparability of patients prescribed dabigatran or vitamin K antagonists (VKA).
methods: The first region analyzed in Phase II was North America and patients were characterized using propensity score distributions derived from 
cross-sectional assessments to describe factors influencing the probability that a patient would receive one treatment or the other.
results: 536 patients initiating dabigatran (59.0% male; median age 71 years) were compared to 488 beginning VKA (53.7% male; median age 
74 years). Hypertension and history of stroke were balanced across the two groups (prevalences ~80% and ~10%, respectively), while age, CHADS2 
scores, creatinine clearance (CrCl) and history of venous thromboembolism (VTE) differed. Compared to those prescribed dabigatran, patients 
given VKA more often had CHADS2 scores ≥2 (68.0 versus 54.3%), lower median CrCl (70.5 versus 82.2 ml/min) and prior VTE (2.7 versus 0.4%). 
Propensity score distributions for the two groups overlapped for 99.3% of patients when the model contained a pre-specified subset of risk factors 
for stroke and bleeding, and for 96.3% of patients when the model included all collected baseline characteristics.
conclusions: North American data collected during Phase II indicate that patients selected for dabigatran were similar to those given VKA based 
on extensively overlapping propensity score distributions. Such overlap is important to ensure the comparability of patients initiating treatment in a 
study of the safety and effectiveness of novel oral anticoagulants and VKA in clinical practice.
